April 22, 2026 4:38pm

Uncertainty creates volatile … traders still remain fidgety yet roll pricing upward before a who-knows-what-case war scenario given stocks’ recovery from Tuesday’s debacle 

Indexes, software and tech rebounds on earnings reports, Iran ceasefire extension while the fear index VIX wraps at 18.74 <see the weeks’ numbers below>

As the breath of the market widens

Pre-open signals: 2 Hits <Sell into Strength> and 1 Miss <although a sell made $>

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

RMi Pre-opening: More of the same, ambiguity … https://www.regmedinvestors.com/articles/14391

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Wednesday: The Dow closed UP +340.65 points or +0.69%, the S&P closed UP +73.89 points or +1.05% while the Nasdaq closed UP +397.603 points or +1.64%

  • Theme of the session: Iran ceasefire extends

Wednesday (my) 40-company covered sector’s advance/decline line opened positive with 24 incliners, 13 decliners and 3 flats, ending with a positive close of 30 incliner, 9 decliners and 1 flat

  • It’s time for fundamentals and trial “stones” to be MORE considered VALUED

The CBOE Fear (VIX) index, Wednesday closed at 18.74, after Tuesday’s 20.59, Monday’s 19.04, Friday’s 17.39, Thursday’s17.81 and last Wednesday’s 18.17 

Metrics: Wednesday …

  • The RUT was up +20.08 points or +0.73%,
  • The XLV was up +0.42 points or +0.29%,
  • The NBI was up +5.52 points or +0.09%;
  • The XBI was up +0.91 points or +0.67%
  • The IWM was up +1.95 or +0.71%;
  • The IBB was up +0.91 points or +0.67%,
  • The VIX was down -3.90 points or -0.76% at to 18.74
  • The SPX was up +73.11 or +1.03% to 7,120.82

 

Q2/26 – 1 holiday, 1 neutral, 5 negative and 8 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Wednesday Closing UP (10 of 30) 

  • Arrowhead Pharmaceuticals (ARWR +$2.87 after Tuesday’s +$1.80),
  • Alnylam Pharmaceuticals (ALNY +$2.15 after Tuesday’s -$2.51 after Monday’s +$1.28),
  • Moderna (MRNA +$1.37),
  • Intellia Therapeutics (NTLA +$1.26 after Tuesday’s +$0.10 after Monday’s +$0.26),
  • Supernus Therapeutics (SUPN +$1.17 after Tuesday’s -$2.13),
  • AxoGen (AXGN +$1.11 after Tuesday’s -$1.34 after Monday’s -$1.27),
  • Vertex (VRTX +$1.08 after Tuesday’s -$2.59 after Monday’s -$2.02),
  • Beam Therapeutics (BEAM +$1.00),
  • CRISPR Therapeutics (CRSP +$0.88 after Tuesday’s -$2.15 after Monday’s -$0.30),
  • Vericel (VCEL +$0.70 after Tuesday’s -$2.14 after Monday’s +$0.13),

Flat (1)

  • Generation Bio (GBIO) – acquired

Wednesday’s Closing DOWN (9 of 9): 

  • BioNTech (BNTX -$3.00 after Tuesday’s +$6.41 after Monday’s +$2.27),
  • IQVA Holdings (IQV -$0.47 after Tuesday’s -$1.18 after Monday’s +$0.41),
  • Mesoblast (MESO -$0.44),
  • Capricor Therapeutics (CAPR -$0.34 after Tuesday’s +$1.13 after Monday’s -$0.49),
  • Sarepta Therapeutics (SUPN -$0.04 after Tuesday’s -$0.74),
  • Brainstorm Cell Therapeutics (BCLI -$0.02),
  • Precigen (PGEN -$0.02),
  • Cellectis SA (CLLS -$0.02),
  • Entrada Therapeutics (TRDA -$0.02),

 

 

The Bottom Line: More of the … WHY and a lot of what ifs …

I believe today is a rope-a-dope move by markets masking coming moves although if one looked at the migration of positive versus negative sector closes – trading made the move.

  • The rope-a-dope is a boxing fighting technique in which one contender leans against the ropes of the boxing ring to draw non-injuring offensive punches in an effort to tire out the opponent and, while he is on the ropes, tries to execute devastating offensive punches.
  • By being in a defensive posture and being prepared for the incoming blows, the boxer decreases his chances of being caught with a clean flush blow. <Wikipedia>

indexes climbed on Wednesday after President Trump extended a ceasefire deadline tied to Iran, helping the Nasdaq touch a fresh intraday high as investors tracked both geopolitical risks and a softer tone in rates.

  • Treasury yields were mixed, with the 10-year note edging lower and the 2-year yield moving higher.
  • While crude oil futures climbed to about $92 a barrel and Brent traded near $101.

 

April 4th Week:

  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

April 3rd Week:

  • 4/17 - Friday closed positive with 33 incliners, 5 decliners and 2 flats
  • 4/16 - Thursday closed negative with 12 incliners, 26 decliners and 2 flats
  • 4/15 – Wednesday closed positive with 26 incliners, 12 decliners and 2 flats
  • 4/14 - Tuesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 4/13 - Monday closed positive with 33 incliners, 5 decliners and 2 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28
  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • IQVIA Holdings (IQV) – Tuesday, 5/5

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Moderna (MRNA)
  • Tuesday: BioNTech (BNTX), Arrowhead Pharmaceuticals (ARWR) and Capricor Therapeutics (CAPR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and BioLife Solutions BLFS)

The worst three (3) in the session: Losers’

  • Wednesday:  BioNTech (BNTX), IQVA Holdings (IQV) and Mesoblast (MESO)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Monday: Vertex (VRTX), AxoGen (AXGN) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.